| Jul 1 |
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
|
| Jun 20 |
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
|
| Jun 18 |
Oppenheimer cuts Ovid to perform, cites uncertainty over lead drug
|
| Jun 18 |
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
|
| Jun 18 |
Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
|
| Jun 17 |
Top Midday Decliners
|
| Jun 17 |
Ovid stock plunges 66% on failed studies for soticlestat
|
| Jun 17 |
Sector Update: Health Care Stocks Decline Premarket Monday
|
| Jun 17 |
Takeda drug for rare types of epilepsy misses goal in late-stage trial
|
| Jun 17 |
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
|
